StockData
RedHill Biopharma Ltd. logo

RedHill Biopharma Ltd. (RDHL) shareholders

RDHLNasdaqPharmaceutical Preparations
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Apr 27, 2026Score 0/30
$0.35−0.01 (-2.91%)

Close on Nov 17, 2026Market cap $1.78MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
0.0%
0M of 50.92B shares
Institutional holders
14
2 new, 4 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 3 sales
Net sold $1.43K

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
SC-Sigma Global Partners, LP
Joint filing with YA II PN, Ltd. (9.90%), YA Global Investments II (U.S.), LP (9.90%) and 5 more
508,7239.90%13G (passive)Dec 19, 2025
Alumni Capital LP
Joint filing with Alumni Capital GP LLC (9.99%), Ashkan Mapar (9.99%)
369,3739.99%13G (passive)Jun 20, 2025
Hal Mintz––13G (passive) amendmentDec 31, 2023

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of RDHLValueChange% of portfolio
Yorkville Advisors Global, LP122,1310.00%$106.68K−228,7390.12%
Gagnon Securities LLC88,4050.00%$74.70K–0.01%
Citadel Advisors LLC65,3210.00%$55.20K+44,6480.00%
Rhumbline Advisers13,7550.00%$11.62K+8,6390.00%
Lido Advisors, LLC11,0090.00%$9.30KNew0.00%
GAMMA Investing LLC6,9570.00%$5.88K+2730.00%
Citigroup Inc4,3780.00%$3.70KNew0.00%
Federation des caisses Desjardins du Quebec3,3880.00%$2.86K–0.00%
Royal Bank of Canada3510.00%$0+3500.00%
UBS Group AG1000.00%$85−7260.00%
SBI Securities Co., Ltd.150.00%$13+110.00%
Smartleaf Asset Management LLC50.00%$4–0.00%
Vermillion Wealth Management, Inc.20.00%$2–0.00%
Morgan Stanley10.00%$1–0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026140M0.0%2 / 52 / 40M0M
Q1 2026161M0.0%3 / 51 / 40M0M
Q4 2025170M0.0%4 / 33 / 10M0M
Q3 2025140M0.0%4 / 05 / 20M0M
Q2 2025120M0.0%1 / 53 / 10M0M
Q1 2025120M0.0%2 / 33 / 10M0M
Q4 2024110M0.0%3 / 41 / 30M0M
Q3 2024110M0.0%3 / 35 / 100M0M
Q2 2024180M0.0%3 / 55 / 20M0M
Q1 2024170M0.0%3 / 61 / 50M0M
Q4 2023190M0.0%5 / 61 / 50M0M
Q3 2023190M0.0%3 / 54 / 40M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Dror Ben-AsherChief Executive Officer, Director441,350,0000.87%Mar 18, 2026
Rick D. ScruggsChief Commercial Officer, Director312,500,0000.61%Mar 18, 2026
Gilead RadayChief Operating Officer176,910,0000.35%Oct 6, 2026
Adi FrishChief Corp & BD Officer276,810,0000.54%Mar 18, 2026
Guy Joel GoldbergChief Business Officer305,720,0000.60%Mar 18, 2026
Razi IngberChief Financial Officer277,560,0000.55%Mar 18, 2026
Ofer TsimchiDirector146,250,0000.29%Mar 19, 2026
Kenneth ReedDirector105,200,0000.21%Mar 18, 2026
Shmuel CabillyDirector105,200,0000.21%Mar 18, 2026
Roni MamlukDirector103,500,0000.20%Mar 18, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Gilead Raday
Chief Operating Officer
Oct 1, 2026Sale−14,310,000$0.00$1.43K176,910,000
Gilead Raday
Chief Operating Officer
Jul 10, 2026Sale−14,130,000––218,780,000
Gilead Raday
Chief Operating Officer
Apr 6, 2026Sale−15,740,000––261,060,000

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
–
0M shares short
Days to cover
1.0
At 0M shares a day
Change since last report
-52.3%
From 0M shares
Short volume, 20 days
27.5%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of RedHill Biopharma's stock actually held short. Settlement fails (shares not delivered on time) peaked at 736,481 shares on Sep 1, 2026 over the last 90 days.

See a number that looks wrong?